In vitro study of the effects of cysteinyl leukotrienes on human vascular preparations;Etude in vitro des effets des cysteinyl leucotrienes sur des preparations vasculaires d'origine humaine

Therapie

Volumn 55, Issue 1, 2000, Pages 29-33

  Stanke Labesque, F ^a   Cracowski, J L ^a   Devillier, P ^a   Bessard, G ^a  

^a UNIV GRENOBLE ALPES   (France)

Author keywords

Human vessels; In vitro studies; Leukotrienes

Indexed keywords

LEUKOTRIENE E4; NORADRENALIN; PEPTIDOLEUKOTRIENE;

BLOOD VESSEL TONE; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CONFERENCE PAPER; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; URINARY EXCRETION; VASOCONSTRICTION; VASODILATATION;

BLOOD VESSELS; HUMANS; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENES; MUSCLE, SMOOTH, VASCULAR;

EID: 0034037449     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Gorenne I, Norel X, Brink C. Cysteinyl leukotriene receptor in the human lung: what's new? Trends Pharmacol Sci 1996; 17: 342-345.
2. Labat C, Ortiz JL, Norel X et al. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther 1992; 263: 800-805.
3. 4 relaxes canine renal and superior mesenteric arteries. Circ Res 1985; 57: 323-329.
4. Berkowitz BA, Zabko-Potapovich B, Valocik R et al. Effects of leukotrienes on the vasculature and blood pressure of different species. J Pharmacol Exp Ther 1984; 229: 105-112.
5. 4 in neonates with hypoxemia and pulmonary hypertension. N Engl J Med 1983; 309: 77-80.
6. Cary M, Korley V, Willerson JT et al. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992; 85: 230-236.
7. Tagari P, Ethier D, Carry M et al. Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay. Clin Chem 1989; 35: 388-391.
8. Ford-Hutchinson AW, Gresser M, Young RN. 5-lipoxygenase. Annu Rev Biochem 1994; 63: 383-417.
9. Kennedy BP, Diehl RE, Boie Y et al. Gene characterization and promoter analysis of the human 5-lipoxygenase activating protein (FLAP). J Biol Chem 1991; 266: 8511-8516.
10. Pedersen KE, Bochner BS, Undem BJ. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther 1997; 281: 655-662.
11. Allen SP, Chester AH, Dashwood MR et al. Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery. Implication for graft performance. Circulation 1994; 90: 515-524.
12. Ortiz JL Gorenne I, Cortijo J et al. Leukotriene receptor on human pulmonary vascular endothelium. Br J Pharmacol 1995; 115: 1382-1386.
13. 4 on human isolated saphenous veins. Br J Clin Pharmacol 1992; 34: 409-414.
14. Allen S, Dashwood M, Morisson K et al. Differential leukotriene constrictor responses in human atherosclerotic coronary artery. Circulation 1998; 97: 2406-2413.
15. 4 in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis 1993; 4: 899-904.
16. Stanke F, Devillier P, Chavanon O et al. Modulation of angiotensin II-induced contraction by eicosanoids on human internal mammary artery. Fund Clin Pharmacol 1998; 12: 365.
17. Stern N, Nozawa K, Golub M et al. The lipoxygenase inhibitor phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Am J Hypertens 1993; 6: 52-58.
18. Nozawa K, Tuck ML, Golub M et al. Inhibition of lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats. Am J Physiol 1990; 259: H1774-H1780.
19. Devillier P, Bessard G, Advenier C. Les antagonistes des leucotriènes: une approche nouvelle du traitement de l'asthme. Rev Mal Resp 1997; 14: 159-170.
20. Devillier P, Millart H, Advenier C. Les anti-leucotriènes: leur positionnement dans l'asthme. Rev Med Brux 1997; 18: 279-283.